Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.

In this study, the adjuvanticity of 2 nontoxic derivatives (LTK63 and LTR72) of heat-labile enterotoxin of Escherichia coli (LT) was evaluated and was compared with that of a cytosine phosphodiester-guanine (CpG) motif, after transcutaneous immunization with tetanus toxoid (TT). TT plus LTR72 elicited the strongest antibody responses, compared with those elicited by the other vaccines (TT, TT plus LTK63, TT plus CpG, and TT plus LTK63 plus CpG); it neutralized the toxin and conferred full protection after passive transfer in mice. Preexisting immunity to LT mutants did not adversely affect their adjuvant potency. Both LTK63 and LTR72 promoted the induction of IgG1 antibodies. In contrast, mice receiving either CpG motif alone or CpG motif plus LTK63 produced strong IgG2a anti-TT antibody responses. Overall, these findings demonstrate that mutants of enterotoxins with reduced toxicity are effective adjuvants for transcutaneous immunization.

[1]  G. Dougan,et al.  Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. , 2003, Vaccine.

[2]  S. Muller,et al.  Immunity under the skin: potential application for topical delivery of vaccines. , 2003, Vaccine.

[3]  George K. Lewis,et al.  Cholera Toxin and Heat-Labile Enterotoxin Activate Human Monocyte-Derived Dendritic Cells and Dominantly Inhibit Cytokine Production through a Cyclic AMP-Dependent Pathway , 2002, Infection and Immunity.

[4]  A. Sharpe,et al.  Role of B7 Costimulatory Molecules in the Adjuvant Activity of the Heat-Labile Enterotoxin of Escherichia coli1 , 2002, The Journal of Immunology.

[5]  R. Rappuoli,et al.  The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin , 2002, Infection and Immunity.

[6]  R. Mumper,et al.  Topical immunization using nanoengineered genetic vaccines. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[7]  M. Wolf,et al.  Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously , 2002, Infection and Immunity.

[8]  S. Muller,et al.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells , 2002, Immunology.

[9]  C. Elmets,et al.  Protection against Tetanus by Needle-Free Inoculation of Adenovirus-Vectored Nasal and Epicutaneous Vaccines , 2001, Journal of Virology.

[10]  G. Dougan,et al.  Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. , 2001, Vaccine.

[11]  S. Muller,et al.  Immunization onto bare skin with heat‐labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge , 2001, Immunology.

[12]  J. Donnelly,et al.  Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. , 2001, The Journal of infectious diseases.

[13]  G. Glenn,et al.  Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. , 2001, Critical reviews in therapeutic drug carrier systems.

[14]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[15]  H. Uchi,et al.  Cytokines and chemokines in the epidermis. , 2000, Journal of dermatological science.

[16]  C. Alving,et al.  Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.

[17]  P. Iversen,et al.  Transdermal delivery of antisense compounds. , 2000, Advanced drug delivery reviews.

[18]  G. Dougan,et al.  LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. , 2000, International journal of medical microbiology : IJMM.

[19]  C. Alving,et al.  Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants , 2000, Infection and Immunity.

[20]  A. Krieg,et al.  The role of CpG motifs in innate immunity. , 2000, Current opinion in immunology.

[21]  B. Ryffel,et al.  Migration of Langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF‐α and IL‐1 β , 1999, Journal of leukocyte biology.

[22]  P. Amerio,et al.  Role of cytokines in epidermal Langerhans cell migration , 1999, Journal of leukocyte biology.

[23]  F C Kafatos,et al.  Phylogenetic perspectives in innate immunity. , 1999, Science.

[24]  G. Matyas,et al.  Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins as Antigens and Adjuvants , 1999, Infection and Immunity.

[25]  L. Simonsen,et al.  Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. , 1999, Bulletin of the World Health Organization.

[26]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[27]  K. Heeg,et al.  Immunostimulatory DNA: Sequence‐dependent production of potentially harmful or useful cytokines , 1997, European journal of immunology.

[28]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[29]  D. Sesardic,et al.  Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests. , 1994, Vaccine.

[30]  D. Sesardic,et al.  The First International Standard for Antitetanus Immunoglobulin, Human; pharmaceutical evaluation and international collaborative study. , 1993, Biologicals : journal of the International Association of Biological Standardization.

[31]  B. Spangler,et al.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. , 1992, Microbiological reviews.

[32]  G. R. Pullen,et al.  Antibody avidity determination by ELISA using thiocyanate elution. , 1986, Journal of immunological methods.